Gilead Sciences and Terray Therapeutics Forge AI-Powered Drug Discovery Partnership

Gilead Sciences and Terray Therapeutics Announce Strategic Collaboration

Gilead Sciences, Inc. and Terray Therapeutics have entered into a strategic partnership to accelerate drug discovery using artificial intelligence (AI) technology. The collaboration aims to identify and develop small-molecule therapies across multiple targets, leveraging Terray's innovative tNova platform 1

1

The tNova Platform: Merging AI with Drug Discovery

Terray's tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug-discovery engine. This cutting-edge approach is designed to efficiently identify small-molecule therapeutics against a set of targets selected by Gilead 2

2

Financial Terms and Impact

While specific financial details were not disclosed, the agreement includes:

1. An upfront payment to Terray
2. Potential milestone payments for preclinical, clinical, and sales achievements
3. Tiered royalties on net sales of any commercialized products

Gilead expects the transaction to have a minimal impact on its 2024 earnings, reducing both GAAP and non-GAAP EPS by approximately $0.01 1

1

2

Strategic Implications for Gilead

This collaboration aligns with Gilead's focus on innovative medicines targeting life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Flavius Martin, M.D., Gilead's Executive Vice President of Research, emphasized the potential of Terray's platform to enhance their internal research capabilities 2

2

Gilead's Recent Developments

In addition to this partnership, Gilead has made several other notable advancements:

1. Received a positive opinion from the European Medicines Agency for seladelpar, a treatment for primary biliary cholangitis
2. Reported promising interim results from the Phase 3 ASSURE study on Livdelzi
3. Entered an exclusive agreement with Tubulis to develop an antibody-drug conjugate for solid tumor treatment 2

   2

Related Stories

Bayer partners with Iambic Therapeutics to accelerate drug discovery using AI technology

Takeda inks $1.7 billion Iambic deal to accelerate AI drug discovery for cancer treatments

Tevogen Bio Expands AI Collaboration with Microsoft to Accelerate Drug Development

Pharmaceutical Giants Unite to Boost AI-Driven Drug Discovery

Market Position and Analyst Perspectives

Gilead, with annual revenue of $28.3 billion and a 3.35% dividend yield, has shown strong momentum with a 45.8% price return over the past six months. Analysts from Bernstein SocGen Group and Deutsche Bank have maintained positive outlooks on the company, particularly noting the potential success of HIV treatments like Lenacapavir 2

2

The Future of AI in Drug Discovery

This collaboration between Gilead and Terray Therapeutics represents a growing trend in the pharmaceutical industry of leveraging AI to accelerate drug discovery and development. By combining Gilead's expertise in developing life-saving medications with Terray's AI-powered platform, the partnership aims to address complex challenges in creating new treatments more efficiently 1

1

2